Nexalin Gets US Patent for Brain Stimulation Tech in Substance Abuse

Nexalin Technology, Inc., the leader in Deep Intracranial Frequency Stimulation (DIF) of the brain, announced that the United States Patent and Trademark Office (USPTO) has officially granted its patent titled “Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD).”

This milestone further strengthens Nexalin’s intellectual property portfolio and affirms the potential of its proprietary Deep Intracranial Frequency Stimulation (DIFS) technology, a non-invasive and drug-free solution designed to aid individuals struggling with substance use disorders (SUDs), including opioid use disorder (OUD), alcohol use disorder (AUD), and stimulant addiction such as cocaine and methamphetamine dependence. By applying non-invasive deep-brain stimulation at dynamic frequencies, DIFS technology may help regulate neural pathways linked to addiction and withdrawal symptoms, offering an alternative treatment pathway for individuals seeking recovery.

Mark White, CEO of Nexalin Technology, remarked, “Securing this patent grant from the USPTO is a significant achievement for Nexalin as we continue to push the boundaries of non-invasive brain stimulation. Substance use disorders remain one of the greatest public health challenges worldwide, and our DIFS technology has the potential to introduce a transformative approach to treatment. With this official patent in place, we are further cementing our role as pioneers in the field of addiction and mental health therapy with a safe and effective brain-based treatment. Chronic relapse among individuals with substance use disorders is often driven by underlying anxiety, depression, and persistent cravings. Our DIFS technology is designed to address these core symptoms through targeted neuromodulation. By potentially alleviating anxiety and depression, DIFS may also reduce the cravings that lead to relapse-offering a promising pathway to improved treatment outcomes and long-term recovery.”

Millions of individuals worldwide are affected by substance use disorders, including opioid dependency, alcoholism, and stimulant abuse. While traditional treatment methods such as medication-assisted therapy (MAT) and behavioural interventions exist, they come with accessibility issues, pharmaceutical dependency, and potential side effects. Nexalin’s DIFS technology represents a forward-thinking alternative, aiming to ease withdrawal symptoms and support long-term recovery without the risks associated with conventional therapies.

David Owens, CMO of Nexalin Technology, added, “Addressing the addiction crisis requires new, effective, and non-invasive treatment options. The official granting of this patent confirms the innovative nature of our DIFS technology and underscores its potential impact on addiction treatment. Nexalin remains dedicated to advancing non-invasive solutions that meet pressing medical needs, and this patent approval marks another step in our mission to redefine care standards in addiction and mental health treatment.”

This patent joins Nexalin’s expanding intellectual property portfolio, which includes groundbreaking developments in non-invasive neuromodulation for addiction, mental health, and neurological disorders. As the company continues to refine its innovative treatment solutions, Nexalin remains committed to delivering breakthrough technologies that improve patient care and transform recovery strategies.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!